Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 1.00 |
| ▸ | FASN | P49327 | 3/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PADI4 | Q9UM07 | 4/20 | 0.46 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851553 | 0.86 | CSF1R (0.76) | CSF1RFASNKITFLT3IDO1 | |
| SCHEMBL1502017 | 0.83 | CSF1R (1.00) | CSF1RKITFLT3PADI4 | |
| SCHEMBL4851373 | 0.83 | CSF1R (0.75) | CSF1RIDO1MEN1KMT2APADI4 | |
| SCHEMBL1502413 | 0.76 | CSF1R (0.62) | CSF1RFASNIDO1MEN1KMT2A | |
| SCHEMBL4452967 | 0.76 | FASN (1.00) | CSF1RFASNMEN1KMT2APADI4 | |
| SCHEMBL4847246 | 0.74 | CSF1R (1.00) | CSF1RFASNKITFLT3MEN1 | |
| SCHEMBL4849649 | 0.74 | CSF1R (1.00) | CSF1RFASNKITFLT3MEN1 | |
| SCHEMBL4851425 | 0.73 | CSF1R (0.64) | CSF1RFASNKITFLT3MEN1 | |
| SCHEMBL29611969 | 0.72 | FASN (0.66) | CSF1RFASNMEN1KMT2APADI4 | |
| SCHEMBL19952892 | 0.72 | FASN (0.66) | CSF1RFASNMEN1KMT2APADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | claimed |
| CN-1867334-A | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-22 | — | — | CN | claimed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | claimed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | claimed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | claimed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| CN-1867334-A | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-22 | — | — | CN | disclosed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | FLT3, ABL1, FES | CSF1R 192/4885FASN 1593/4885KIT 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.